Nephrotoxicity of New Antibiotics: A Systematic Review

QR Code

Nephrotoxicity of New Antibiotics: A Systematic Review

Drug-induced nephrotoxicity is a common and serious problem in clinical practice. We conducted a systematic review of studies reporting nephrotoxicity events associated with antibiotics approved since 2018. The agents assessed included aztreonam/avibactam, cefepime/enmetazobactam, cefiderocol, cefto...

Full description

Saved in:

Bibliographic Details
Main Authors:	Panagiotis Stathopoulos, Laura T. Romanos, Charalampos Loutradis, Matthew E. Falagas
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Toxics
Subjects:	aztreonam/avibactam cefepime/enmetazobactam cefiderocol ceftobiprole contezolid gepotidacin
Online Access:	https://www.mdpi.com/2305-6304/13/7/606
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals
by: Lalitagauri M Deshpande, et al.
Published: (2025-09-01)

Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis
by: Giorgia Fabrizio, et al.
Published: (2025-06-01)

Mortality of metallo-β-lactamase-producing Enterobacterales bacteremias with combined ceftazidime–avibactam plus aztreonam vs. other active antibiotics: a multicenter target trial emulationResearch in context
by: Ivan Alfredo Huespe, et al.
Published: (2025-09-01)

A New Antibiotic for Treatment of Urinary Tract Infection -A Review Study
by: M Arefnezhad, et al.
Published: (2024-12-01)

Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019–2023)
by: Helio S. Sader, et al.
Published: (2025-05-01)

Whole-Genome Analysis of NDM-Producing Providencia hangzhouensis Associated With Recurrent Bacteraemia with Rapid Development of Aztreonam-Avibactam Resistance
by: Ka Lip Chew, et al.
Published: (2025-07-01)

The use of ceftobiprole in treatment pathways in Spain: An expert panel review
by: Carmen Hidalgo-Tenorio, et al.
Published: (2025-06-01)

Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-Producing <i>Enterobacterales</i>: A Comparative Evaluation Using the CLSI and EUCAST Methods
by: Linda Mei-Wah Chan, et al.
Published: (2025-07-01)

Infections Caused by Carbapenem-Resistant Enterobacterales: Epidemiology, Clinical Significance, and Possibilities for Antibiotic Therapy Optimization
by: S. V. Yakovlev, et al.
Published: (2020-08-01)

Straight to the Dome - Cefepime Induced Neurotoxicity
by: Hannah Starbuck, et al.
Published: (2025-06-01)

The First Experience of Combined Use of Cefepime/Sulbactam and Aztreonam in ICU Patients with Nosocomial Infections Caused by Carbapenem-Resistant Gram-Negative Microorganisms Producing Class B and D Carbapenemases
by: M. P. Suvorova, et al.
Published: (2023-02-01)

Activity of Ceﬁderocol and Other New Antibiotics Against Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> Strains
by: E. V. Karpova, et al.
Published: (2023-02-01)

Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study
by: Wang J, et al.
Published: (2025-07-01)

Susceptibility of HEK293 and RPTEC Cell Lines to Nephrotoxic Effects of Cefuroxime and Cefepime: A Comparative Study
by: V. A. Evteev, et al.
Published: (2023-06-01)

Cefepime Induced Encephalopathy in a Non-dialysis Dependent Chronic Kidney Disease Patient: A Case Report
by: Giritharan Muniandy, et al.
Published: (2023-03-01)

Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa
by: Igor Chebotar, et al.
Published: (2025-08-01)

Optimisation of the Procedure of Cefepime Extraction from Biological Material
by: A. A. Bezyazychnaya, et al.
Published: (2019-09-01)

<i>In vitro</i> activity of cefepime / sulbactam and biapenem against Enterobacterales and <i>Pseudomonas aeruginosa</i> isolated from blood culture from patients with hematological diseases: results of a multicenter study
by: G. A. Klyasova, et al.
Published: (2023-05-01)

The Effect of Cefepime/Fluorothiazinone Compared with Cefepime/Placebo on Clinical Cure and Microbiological Eradication in Patients with Complicated Urinary Tract Infections: A Prospective Randomized Clinical Trial
by: V. B. Beloborodov, et al.
Published: (2025-02-01)

The phenomenon of changing aztreonam susceptibility in Pseudomonas aeruginosa during formation of colistin resistance in vitro
by: Bocharova Yu.A., et al.
Published: (2025-03-01)

Rationale for contemporary antimicrobial treatment of Stenotrophomonas maltophilia: a narrative review
by: John Turnidge, et al.
Published: (2025-06-01)

A systematic review with meta-analysis and indirect comparison of the results of studies evaluating the efficacy and safety of ceftobiprole and ceftaroline in adult patients in the treatment of infections of various localizations
by: Yu. M. Gomon, et al.
Published: (2025-07-01)

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01)

Ceftazidime/avibactam as a possible treatment option for carbapenem-resistant Enterobacterales infections
by: Ana Kaftandzieva, et al.
Published: (2025-12-01)

Addressing antimicrobial resistance: Structural insights into cefiderocol’s mode of action and emerging resistance mechanisms
by: Mohd Zulkifli Salleh
Published: (2025-09-01)

Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistant Acinetobacter baumannii detected from ICU admission screening in Hanoi, Vietnam, 2023
by: Sébastien Boutin, et al.
Published: (2025-07-01)

Cefiderocol susceptibility of Stenotrophomonas maltophilia species complex and carbapenem-resistant Pseudomonas aeruginosa isolates from blood cultures at a university hospital in Tokyo, Japan
by: Wataru Aoki, et al.
Published: (2025-09-01)

Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
by: Strukova E.N., et al.
Published: (2025-03-01)

Biofilm-associated Achromobacter xylosoxidans prosthetic valve infective endocarditis
by: Lisa-Marie Wackernagel, et al.
Published: (2025-09-01)

Cefepime/Sulbactam — A New Innovative Antibiotic for In-Hospital Treatment of Severe Infections and the Implementation of Carbapenem-Replacement Strategy to Contain Antibiotic Resistance
by: S. V. Yakovlev, et al.
Published: (2021-06-01)

Tissue Distribution and Pharmacokinetic Characteristics of Aztreonam Based on Multi-Species PBPK Model
by: Xiao Ye, et al.
Published: (2025-06-01)

Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates
by: Bartosz J. Bartmanski, et al.
Published: (2025-07-01)

Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies
by: G. A. Klyasova
Published: (2020-07-01)

Assessment of clinical effectiveness and safety of ceftazidime-avibactam in ‐treating multi-drug-resistant infections – A retrospective analysis at a tertiary care hospital in Saudi Arabia
by: Eman Merghani Ali, et al.
Published: (2025-09-01)

The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
by: E. N. Strukova, et al.
Published: (2025-04-01)

Prediction of Aztreonam Effectiveness Against <i>Klebsiella pneumoniae</i> Based on the Results of Antimicrobial Susceptibility Testing with Increased Inoculum
by: K. N. Alieva, et al.
Published: (2024-06-01)

Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring
by: E. A. Sokova, et al.
Published: (2022-07-01)

Clinical Eﬃcacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria
by: S. V. Yakovlev
Published: (2021-10-01)

Mortality and clinical outcomes of ceftazidime/avibactam vs best available therapy in treating carbapenem-resistant enterobacterales infections: A retrospective cohort study
by: Nada Alhamed, et al.
Published: (2025-07-01)

CEFPIROME. LITERATURE REVIEW
by: N. V. Dmitrieva
Published: (2014-09-01)